Stroke Recovery and Exosomes and extracellular vesicles: what the trial registry contains

Why this is studied in Stroke Recovery

After ischaemic stroke, some recovery happens spontaneously through oedema resolution and cortical reorganisation, mostly in the first three to six months. Cell therapy is studied both acutely for neuroprotection and chronically for plasticity support — and that spontaneous recovery window is the reason early uncontrolled results in this indication are so often misleading.

What exosomes means in this table

Exosome and extracellular-vesicle products are cell-free: vesicles harvested from cultured cells and given without the cells themselves. They are attractive commercially because they avoid live-cell logistics, and they are regulatorily contested for the same reason — several regulators have issued explicit warnings about unapproved exosome products marketed for human use.

The numbers

Every figure below comes from one reproducible query (stroke x exosome) run against ClinicalTrials.gov API v2 on 2026-08-29.

How mature is this evidence?

There is no confirmatory research programme here — 11 registrations, all early-phase or unlabelled, 2 of them active.

Of those, 2 are marked completed and 0 were terminated, withdrawn or suspended — a stop rate of 0%, worth weighing when a clinic quotes 'ongoing research' as reassurance.

Median planned enrolment is 36 participants (largest single study: 200). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.

Where the studies are

Research is not evenly spread: Taiwan carries about 20% of the country mentions among 9 countries with sites.

Legal pathway differs by country — see where cell therapy is legal, by country.

Who runs them

Lead sponsors split roughly 5 academic or hospital against 2 commercial — a academic profile. Commercial sponsorship is not a red flag by itself, but it changes publication incentives.

• Xuanwu Hospital, Beijing — 2 records
• China Medical University Hospital — 1 record
• S&Ebio Co. Ltd. — 1 record
• Ospedale Civico, Lugano — 1 record
• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine — 1 record
• The Foundation for Orthopaedics and Regenerative Medicine — 1 record

Representative registered studies

Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.

What this page does and does not tell you

A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.

If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.

Frequently asked

How many exosomes studies for Stroke Recovery are recruiting right now?

2 of 11 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.

Is exosomes an approved treatment for Stroke Recovery?

Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 11 registered studies tell you research exists, not that a product cleared review.

How advanced is the research on exosomes for Stroke Recovery?

0 of 11 records carry a Phase 3 or Phase 4 label and 2 are marked completed. Registrations run from 2018 to 2026.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.